Last reviewed · How we verify
gemcitabine; cisplatin or carboplatin; erlotinib
gemcitabine; cisplatin or carboplatin; erlotinib is a Small molecule drug developed by Xinjiang Medical University. It is currently in Phase 3 development. Also known as: tarceva.
At a glance
| Generic name | gemcitabine; cisplatin or carboplatin; erlotinib |
|---|---|
| Also known as | tarceva |
| Sponsor | Xinjiang Medical University |
| Modality | Small molecule |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) (NA)
- A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site (PHASE2)
- Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFR (PHASE3)
- Radical Treatment of Synchronous Oligometastatic Non-Small Cell Lung Carcinoma (NA)
- A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT) (PHASE2)
- Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) (PHASE1)
- Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma (PHASE2)
- PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- gemcitabine; cisplatin or carboplatin; erlotinib CI brief — competitive landscape report
- gemcitabine; cisplatin or carboplatin; erlotinib updates RSS · CI watch RSS
- Xinjiang Medical University portfolio CI
Frequently asked questions about gemcitabine; cisplatin or carboplatin; erlotinib
What is gemcitabine; cisplatin or carboplatin; erlotinib?
gemcitabine; cisplatin or carboplatin; erlotinib is a Small molecule drug developed by Xinjiang Medical University.
Who makes gemcitabine; cisplatin or carboplatin; erlotinib?
gemcitabine; cisplatin or carboplatin; erlotinib is developed by Xinjiang Medical University (see full Xinjiang Medical University pipeline at /company/xinjiang-medical-university).
Is gemcitabine; cisplatin or carboplatin; erlotinib also known as anything else?
gemcitabine; cisplatin or carboplatin; erlotinib is also known as tarceva.
What development phase is gemcitabine; cisplatin or carboplatin; erlotinib in?
gemcitabine; cisplatin or carboplatin; erlotinib is in Phase 3.
Related
- Manufacturer: Xinjiang Medical University — full pipeline
- Also known as: tarceva
- Compare: gemcitabine; cisplatin or carboplatin; erlotinib vs similar drugs
- Pricing: gemcitabine; cisplatin or carboplatin; erlotinib cost, discount & access